Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

New amylin drugs are lining up to boost GLP-1 weight loss, not replace it

Published Oct 2, 2026
Share:
Summary:
  • In a Phase 2 study, Lilly's eloralintide plus tirzepatide hit 23.3% average weight loss at 48 weeks, versus 14.8% for high dose tirzepatide alone.
  • Side effects pushed 10.8% to 27% of combo patients to stop treatment, compared with 2.9% on tirzepatide alone.
  • Leerink's David Risinger pegs eloralintide at $23.2 billion in annual sales by 2035, with solo launch in 2029 and the combo in 2030.

The pitch: add amylin to go further

GLP-1s are not getting pushed off the stage. They are getting a co star. Drugmakers are leaning into the amylin pathway to complement existing obesity and diabetes drugs, or to open doors for people who do not get enough benefit from GLP-1s.

That showed up in Lilly's latest data. The company tested eloralintide, an amylin analog, alongside tirzepatide in people living with obesity and Type 2 diabetes. After 48 weeks, the highest dose combo group shed an average 23.3% of body weight, compared with 14.8% for those on a high dose of tirzepatide alone, based on an analysis that counts people as remaining on treatment.

"These are encouraging results," said Benjamin Bikman, a Brigham Young University professor and recognized authority on metabolic health and insulin resistance. He noted that adults with Type 2 diabetes tend to lose less weight on these medicines than those without diabetes.

Safety, staying power, and what comes next

The trial was small, so Lilly still has to prove it at scale. Phase 3 studies are slated to start later this year, and the company says it wants to smooth out tolerability for the combo. In the Phase 2 study, discontinuations due to side effects ranged from 10.8% to 27% for people on both drugs, depending on dose, versus 2.9% for tirzepatide alone. "A therapy is only effective if patients can remain on it, so tolerability in Phase 3 will be as important as efficacy," Bikman said. Dr. Caroline Apovian added, "27% is not a good number."

"Patients may not get what they need from a drug like tirzepatide," said Ken Custer, president of Lilly Cardiometabolic Health. "They may not get what they need from a drug like a eloralintide on its own." Bikman also pointed to the combo as a way to help patients who started on tirzepatide and then hit a plateau.

Why amylin, and how Novo fits in

Amylin is a hormone released with insulin that helps dial down hunger and boost satiety, slowing how quickly the stomach empties. It aims for similar outcomes as GLP-1 drugs, but through a different biological route. The thesis is simple: hit multiple pathways and you might get deeper weight loss or broader metabolic gains than pushing one target ever harder.

Novo Nordisk has been on this road for years. Its amylin analog cagrilintide delivered meaningful weight loss on its own in late stage testing, and pairing it with semaglutide as CagriSema lifted results further in clinical studies. Novo says CagriSema is expected to arrive early next year, with a solo cagrilintide and a higher dose CagriSema planned for 2028.

Markets move every day, and most of it never reaches you in time. Get the free Market Briefs daily newsletter and stay ahead of it.

Fresh this week, Novo also highlighted that in a yearlong functional MRI study, CagriSema lowered "food noise" and showed improvements in organ and bone health. The company reported that CagriSema changed how the brain responded to high calorie foods in regions tied to cravings, reward and self control among people who were overweight or had obesity. Novo's chief scientific officer, Martin Holst Lange, said, "The signal in the brain changes in a way that actually is associated with improved quality of life."

Novo is advancing another candidate, amycretin, also called zenagamtide, a single molecule designed to hit both GLP-1 and amylin. It is being tested as a weekly injection and a daily pill, and delivered encouraging mid stage data earlier this year.

A quick rewind and what it means for your money

The new wave is long acting, so weekly dosing is the goal. More broadly, the playbook is shifting toward multi hormone medicines. Tirzepatide already combines GLP-1 and GIP. Lilly's retatrutide adds glucagon and, in published data, has produced substantial weight reduction as well as decreases in hepatic fat, triglyceride levels, and fasting insulin.

On the commercial side, Leerink Partners analyst David Risinger thinks eloralintide could be a whale. He sees "millions of individuals, potentially over 10 million people," who tried a GLP-1 and did not get there due to efficacy, tolerability or genetics. His model projects that by the close of 2035, eloralintide products could generate $23.2 billion annually, with the standalone debut in 2029 and the combination following in 2030. He also sees more upside in the standalone drug given the large pool of patients who did not succeed on existing GLP-1s.

For regular investors, the takeaway is more choice ahead for people managing obesity and Type 2 diabetes, spanning weekly injections and possibly daily pills. The open question is whether amylin based combos can keep the efficacy edge while staying tolerable enough for people to stick with them. The next few years of trial readouts and launches will tell you if this becomes a durable, patient friendly category or just a flashy add on.

The money story behind the headlines is usually the part that matters. Join Market Briefs free and get it every morning.

Disclosure

Recent News

1 2 3 … 133

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 20, 2026
Anthropic Stock at $1.5 Trillion: Why This IPO Isn't Amazon in 1997

Anthropic has gone public at a valuation of about $1.5 trillion, while Amazon went public in 1997 at around $440 million. Anthropic has about $33 billion in revenue this year and no profit, and investors are paying more than 40 times its sales, against about 3 times for Amazon. Briefs Finance CEO Jaspreet Singh says nobody knows what comes next, and that long-term investors use downturns to buy instead of panic selling.

Read More
November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
1 2 3 … 33
Share via
Copy link